Atlas Trials

Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections

Clinical trial NCT01147640 · COMPLETED

Trial details

NCT number
NCT01147640
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Complicated Intra-abdominal Infection
Start date
2010-06-25
Primary completion
2011-02-20
Enrollment
122

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.